Biomarker-driven molecular imaging probes in radiotherapy

Biomarker-driven molecular imaging probes in radiotherapy

2024.07.02 | Haonan Li, Qiyong Gong, Kui Luo
The article "Biomarker-driven molecular imaging probes in radiotherapy" by Haonan Li, Qiyong Gong, and Kui Luo reviews the role of biomarker-driven molecular imaging in precision radiotherapy. The authors highlight the importance of molecular imaging probes, particularly nanoprobes, in monitoring the spatiotemporal distribution of biomarkers during radiotherapy, which can reveal tumor-killing mechanisms and therapy-induced adverse effects. The review covers two main aspects: clinically investigated and emerging imaging biomarkers associated with radiotherapy, and the instrumental roles, functions, and activatable mechanisms of molecular imaging probes in the radiotherapy workflow. Key findings include: 1. **Imaging Biomarkers**: Various imaging biomarkers have been explored, including hypoxia, metabolic responses, tumor-associated surface receptors, radioresistant cell types, and redox status. These biomarkers are used for planning, patient stratification, response assessment, and toxicity prediction. 2. **Molecular Imaging Probes**: Nanoprobes, with their modifiability and multiple imaging modalities, have been developed to monitor the tumor microenvironment before, during, and after radiation-based therapies. These probes can be tuned to target well-established biomarkers, providing dynamic and spatiotemporal information for personalized precision therapy. 3. **Application in Radiotherapy Workflow**: Imaging probes are used in radiotherapy planning to accurately determine the gross tumor volume and reduce planning target volume margins. They are also used for patient stratification to identify patients who will benefit from specific therapeutic methods. Additionally, these probes help in assessing early tumor response, measuring radiosensitivity, and predicting radiotherapy-induced toxicity. The authors conclude that biomarker-driven molecular imaging probes are essential for precision radiotherapy, but robust validation of imaging biomarkers and rational design strategies of probes are still needed. Multi-center collaboration involving large cohorts of patients is crucial to establish the correlation between imaging biomarkers and radiotherapeutic outcomes/toxicities.The article "Biomarker-driven molecular imaging probes in radiotherapy" by Haonan Li, Qiyong Gong, and Kui Luo reviews the role of biomarker-driven molecular imaging in precision radiotherapy. The authors highlight the importance of molecular imaging probes, particularly nanoprobes, in monitoring the spatiotemporal distribution of biomarkers during radiotherapy, which can reveal tumor-killing mechanisms and therapy-induced adverse effects. The review covers two main aspects: clinically investigated and emerging imaging biomarkers associated with radiotherapy, and the instrumental roles, functions, and activatable mechanisms of molecular imaging probes in the radiotherapy workflow. Key findings include: 1. **Imaging Biomarkers**: Various imaging biomarkers have been explored, including hypoxia, metabolic responses, tumor-associated surface receptors, radioresistant cell types, and redox status. These biomarkers are used for planning, patient stratification, response assessment, and toxicity prediction. 2. **Molecular Imaging Probes**: Nanoprobes, with their modifiability and multiple imaging modalities, have been developed to monitor the tumor microenvironment before, during, and after radiation-based therapies. These probes can be tuned to target well-established biomarkers, providing dynamic and spatiotemporal information for personalized precision therapy. 3. **Application in Radiotherapy Workflow**: Imaging probes are used in radiotherapy planning to accurately determine the gross tumor volume and reduce planning target volume margins. They are also used for patient stratification to identify patients who will benefit from specific therapeutic methods. Additionally, these probes help in assessing early tumor response, measuring radiosensitivity, and predicting radiotherapy-induced toxicity. The authors conclude that biomarker-driven molecular imaging probes are essential for precision radiotherapy, but robust validation of imaging biomarkers and rational design strategies of probes are still needed. Multi-center collaboration involving large cohorts of patients is crucial to establish the correlation between imaging biomarkers and radiotherapeutic outcomes/toxicities.
Reach us at info@study.space